Pharmacokinetics of Ceftazidime/Avibactam Following Intravenous Administration in Rabbits: Developing the Preclinical Foundation for Treatment of KPC-Kp Pneumonia in Immunocompromised Patients
نویسندگان
چکیده
be critical to prevent attachment of pathogen. BF production increased or remained unchanged in the presence of amikacin. Due to toxicity concerns and variation in resistance patterns, minocycline is a viable treatment option against A. baumannii. Additional studies are warranted. Disclosures. K. LaPlante, Merck: Grant Investigator, Grant recipient. Pfizer: Grant Investigator, Grant recipient. Cempra: Scientific Advisor, Consulting fee. The Medicines Company: Grant Investigator, Grant recipient. Allergan: Scientific Advisor, Consulting fee. Bard/ Davol: Scientific Advisor, Consulting fee. Ocean Spray: Grant Investigator and Scientific Advisor, Consulting fee and Grant recipient. Zavante: Scientific Advisor, Consulting fee. Achaogen: Scientific Advisor, Consulting fee.
منابع مشابه
First Report of Ceftazidime-Avibactam Resistance in a KPC-3-Expressing Klebsiella pneumoniae Isolate.
Ceftazidime-avibactam is the first antimicrobial approved by the U.S. FDA for the treatment of carbapenem-resistant Enterobacteriaceae. Avibactam, a non-β-lactam β-lactamase inhibitor, inactivates class A serine carbapenemases, including Klebsiella pneumoniae carbapenemase (KPC). We report a KPC-producing K. pneumoniae isolate resistant to ceftazidime-avibactam (MIC, 32/4 μg/ml) from a patient ...
متن کاملPharmacokinetics of ceftazidime in buffalo calves following intravenous and intramuscular administration
The pharmacokinetic parameters of ceftazidime, a third generation cephalosporin, were investigated in six buffalo calves after single intravenous (IV) and intramuscular (IM) administration at a dose rate of 10 mg/kg body weight. Ceftazidime concentrations in plasma and urine were determined by microbiological assay. Ceftazidime disposition was best fitted by a two-compartmental and a one-compar...
متن کاملIn Vitro and In Vivo Activity of Single and Dual Antimicrobial Agents Against KPC-producing Klebsiella pneumoniae
Objectives Options for treatment of infections due to KPC-producing Klebsiella pneumoniae are limited and combination therapy is often recommended. In this report, the in vitro and in vivo activity of potential therapeutic agents and combinations was assessed against four KPC-producing K. pneumoniae isolates. Methods Using clinically relevant concentrations, time-kill experiments and the Gall...
متن کاملSuccessful ceftazidime-avibactam treatment of MDR-KPC-positive Klebsiella pneumoniae infection in a patient with traumatic brain injury
RATIONALE Carbapenem-resistant Enterobacteriaceae infections are a serious health care problem, because of the high mortality. Carbapenem resistance is mainly caused by carbapenemases production, including Klebsiella pneumoniae carbapenemase (KPC). Ceftazidime-avibactam is a new cephalosporin/β-lactamase inhibitor combination for the treatment of complicated urinary, intra-abdominal infections,...
متن کاملRandomized pharmacokinetic and drug–drug interaction studies of ceftazidime, avibactam, and metronidazole in healthy subjects
We assessed pharmacokinetic and safety profiles of ceftazidime-avibactam administered ± metronidazole, and whether drug-drug interactions exist between ceftazidime and avibactam, or ceftazidime-avibactam and metronidazole. The first study (NCT01430910) involved two cohorts of healthy subjects. Cohort 1 received ceftazidime-avibactam (2000-500 mg) as a single infusion or as multiple intravenous ...
متن کامل